These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36469362)

  • 1. Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR.
    Mandell JD; Cannataro VL; Townsend JP
    Cancer Res; 2023 Feb; 83(4):500-505. PubMed ID: 36469362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis.
    Alfaro-Murillo JA; Townsend JP
    Math Biosci; 2023 Dec; 366():109091. PubMed ID: 37996064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
    Yang J; Li H; Li B; Li W; Guo Q; Hu L; Song Z; Zhou B
    Front Oncol; 2021; 11():647598. PubMed ID: 33898318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
    Garcia-Prieto CA; Martínez-Jiménez F; Valencia A; Porta-Pardo E
    Bioinformatics; 2022 Jun; 38(12):3181-3191. PubMed ID: 35512388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
    Yu J; Hu Y; Xu Y; Wang J; Kuang J; Zhang W; Shao J; Guo D; Wang Y
    BMC Cancer; 2019 Mar; 19(1):263. PubMed ID: 30902072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Driver Epistatic Gene Pairs Combining Germline and Somatic Mutations in Cancer.
    Rocha J; Sastre J; Amengual-Cladera E; Hernandez-Rodriguez J; Asensio-Landa V; Heine-Suñer D; Capriotti E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical genomic driver mutations of urethane carcinogenesis.
    Li S; Counter CM
    PLoS One; 2022; 17(4):e0267147. PubMed ID: 35482806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver Variants.
    Landau J; Tsaban L; Yaacov A; Ben Cohen G; Rosenberg S
    Cancer Res; 2023 Jan; 83(1):74-88. PubMed ID: 36264175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
    Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
    BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput Phenotyping of Lung Cancer Somatic Mutations.
    Berger AH; Brooks AN; Wu X; Shrestha Y; Chouinard C; Piccioni F; Bagul M; Kamburov A; Imielinski M; Hogstrom L; Zhu C; Yang X; Pantel S; Sakai R; Watson J; Kaplan N; Campbell JD; Singh S; Root DE; Narayan R; Natoli T; Lahr DL; Tirosh I; Tamayo P; Getz G; Wong B; Doench J; Subramanian A; Golub TR; Meyerson M; Boehm JS
    Cancer Cell; 2016 Aug; 30(2):214-228. PubMed ID: 27478040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
    Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
    Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
    Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
    [No Abstract]   [Full Text] [Related]  

  • 16. [The characteristics of lung adenocarcinoma driver gene variants detected by high-throughput sequencing and quantitative fluorescence PCR].
    Chen LF; Chen XY; Lin J; Yu XB; Jin L
    Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):772-778. PubMed ID: 31594041
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
    Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
    Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
    Planck M; Edlund K; Botling J; Micke P; Isaksson S; Staaf J
    PLoS One; 2013; 8(10):e78614. PubMed ID: 24205279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
    Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
    Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.